NCT02682511Phase 2Active not recruiting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Study sponsor: Cumberland Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-03Actual

Enrollment · participants34Estimated

Source updated2026-09-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-02 · 2 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Jun 2026~~

+ After

Mar 2026

Check registry source

Posted 2026-04-15 · 1 field changed

Primary completion date changed

− Before

~~Feb 2026~~

+ After

Jun 2026

Check registry source

Study details

Conditions studied

Scleroderma, Diffuse; Scleroderma, Systemic; Scleroderma, Limited; Sclerosis, Progressive Systemic; Skin Diseases; Connective Tissue Diseases; Pathologic Processes; Autoimmune Diseases

Treatments or interventions studied

Oral IfetrobanDrugAlso known as Ifetroban
Oral PlaceboDrugAlso known as Ifetroban

Primary outcomes · main study measures

measure: Incidence of adverse events (AEs) and Serious AEs (SAEs); description: Safety is measured using AEs, including clinical significant changes in vital signs, laboratory test abnormalities and clinical tolerability of ifetroban.; timeFrame: 56 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history